Microbiome in Lung Cancer and Other Malignancies

Plain-language summary

This study examines the microbiome in lung cancer and other cancers by collecting nasal, oral, skin and stool samples. Patients over 18 with advanced lung cancer or another solid tumor who will receive systemic treatments such as immunotherapy or chemotherapy may take part. It is a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Taher Abu Hejleh

Intervention

Nasal Swab, Oral Swab, Stool Collection, Microbiome analysis, DNA Banking, Skin Swab

Start date

8/30/2018

Estimated completion

5/9/2022

Countries

United States

Related genes

Locations

• Iowa City, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Patients diagnosed with lung cancer and other malignancies who are candidates for systemic therapies such as immunotherapy and chemotherapy

Eligibility criteria for studying microbiome in patients receiving immunotherapy:

* Patients with advanced/recurrent lung cancer (including both NSCLC and SCLC) and other solid tumors of our study interest (e.g. GU cancer and melanoma, etc.) that initiate a new line of immunotherapy (can be 1st or later line), either alone or in combination with chemotherapy, targeted therapy or other immunotherapy.
* Patients can be in other clinical trials as long as they meet criteria 1.
* Prior treatment with immunotherapy is acceptable as long as criteria 1 is met. For example, a new line therapy with pembrolizumab plus pemetrexed after failing pembrolizumab is considered eligible.
* Patients who are to start immunotherapy maintenance after chemoradiation therapy are eligible (e.g. NSCLC patients who will be on durvalumab maintenance)
* Patients who are to start immunotherapy after local therapies (e.g. radiation, ablation, etc.) are eligible.
* Immunotherapy must have component of anti-PD-1/PD-L1 agents (e.g. nivolumab, pembrolizumab, atezolizumab, durvalumab and avelumab, etc.) or anti-CTLA4 (e.g. ipilimumab)

Exclusion Criteria:

* Patients \< 18 years of age
* Patients that are pregnant
* Patients taking more than 2 alcoholic drinks per day and those using non-medical drugs such as marijuana, cocaine, heroine, etc.